PLIE (Preventing Loss of Independence Through Exercise) is a new program that combines elements of Eastern and Western traditional exercises and emphasizes focus on performing basic functional movements,encouraging social engagement and increasing bodily awareness. In the small group studied, patients would arrive at the exercise facility not remembering that they had been there but would start going through the movements of the routine. This fits with what we know about Alzheimer's : memory for events is impaired but procedural memory holds out and resists declination.
65th Annual AAN meeting San Diego March 2013
In a related study, daily walking has been shown to stabilize Alzheimer's disease across one year.
Arch Gerontol Geriatr. 2013;56(1):96-103
Showing posts with label cognitive function. Show all posts
Showing posts with label cognitive function. Show all posts
Sunday, June 2, 2013
Sunday, March 24, 2013
Alzheimer's Disease Short Course Treatment
This is a follow-up to a previous blog entry related to IVIG treatment of patients with Alzheimer's disease from the Mayo Clinic, Rochester,MN.
Patients with early Alzheimer's disease receiving five doses of intravenous immunoglobulin (IVIG) over an eight week period showed significantly less brain atrophy after 1 year than a placebo group.
The problem is that IVIG is derived from human donor plasma and is extremely scarce supply. It's primary neurologic application to date has been in the treatment of patients with Guillain-Baré syndrome. Production capabilities for all current suppliers could not begin to provide enough for all patients with mild to moderate Alzheimer's disease, let alone the even larger population with mild cognitive impairment.
Therefore, if a short-term dosing regimen is as effective as continuing therapy, it would extend current supplies that may be provided to a larger number of patients.
Kile S, et al "Initial findings of a randomized double-blinded placebo-controlled study of intravenous immunoglobulin in mild cognitive impairment due to Alzheimer disease" AAN 2013; Abstract P01.013.
Patients with early Alzheimer's disease receiving five doses of intravenous immunoglobulin (IVIG) over an eight week period showed significantly less brain atrophy after 1 year than a placebo group.
The problem is that IVIG is derived from human donor plasma and is extremely scarce supply. It's primary neurologic application to date has been in the treatment of patients with Guillain-Baré syndrome. Production capabilities for all current suppliers could not begin to provide enough for all patients with mild to moderate Alzheimer's disease, let alone the even larger population with mild cognitive impairment.
Therefore, if a short-term dosing regimen is as effective as continuing therapy, it would extend current supplies that may be provided to a larger number of patients.
Kile S, et al "Initial findings of a randomized double-blinded placebo-controlled study of intravenous immunoglobulin in mild cognitive impairment due to Alzheimer disease" AAN 2013; Abstract P01.013.
Monday, June 18, 2012
Impaired Cognitive Function in Asymptomatic Carotid artery Disease
From the International Stroke Conference, Dr. C. Balucani enrolled 330 patients from 2005-10. In each of four evaluations, patients with bilateral internal carotid artery stenosis showed significant impairments in both brain hemispheres compared to controls.Patients with unilateral stenosis showed significant impairment only in the brain hemisphere connected to the embarrassed vascular supply.
Subscribe to:
Posts (Atom)